{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:13:12Z","timestamp":1780366392506,"version":"3.54.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>AbobotulinumtoxinA has become well established as a treatment option for moderate to severe glabellar lines since its first aesthetic approval in 2009.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>Pivotal trials leading to regulatory approval showed that abobotulinumtoxinA treatment was associated with high responder rates when defined as achievement of none or mild glabellar lines (0 or 1 on the glabellar line severity scale) and a duration of action of up to 5 months. More recently, the goals for treatment of glabellar lines have shifted toward not only achieving a decrease in glabellar line severity but also ensuring that patients are satisfied with their experience.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>Patients seek an improvement in the appearance of their glabellar lines while maintaining a \u201cnatural look,\u201d fast onset of effect, and long duration of response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Trial designs have evolved to meet these new targets, including expanding the definition of responders to those having at least 1-grade improvement in the glabellar line severity scale score from baseline coupled with the use of subject satisfaction and psychological well-being questionnaires.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The findings demonstrate that abobotulinumtoxinA remains a well-tolerated and consistently effective treatment option associated with a rapid onset of effect, duration of efficacy lasting up to 6 months, and high, long-lasting levels of patient satisfaction.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004347","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T23:53:25Z","timestamp":1724889205000},"page":"S5-S11","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A Review of Current Data on Duration of Effect in Glabellar Lines After Treatment With AbobotulinumtoxinA 50 U"],"prefix":"10.1097","volume":"50","author":[{"given":"Joel L.","family":"Cohen","sequence":"first","affiliation":[{"name":"AboutSkin Dermatology and DermSurgery, Greenwood Village, Colorado;"},{"name":"Department of Dermatology, University of California, Irvine, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ellen","family":"Cox","sequence":"additional","affiliation":[{"name":"Aesthetic Solutions, PA, Chapel Hill, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee Anna","family":"Glaser","sequence":"additional","affiliation":[{"name":"Saint Louis University, St. Louis, Missouri;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Moradi","sequence":"additional","affiliation":[{"name":"Moradi M.D., Vista, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Dayan","sequence":"additional","affiliation":[{"name":"DeNova Research, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Jacob","sequence":"additional","affiliation":[{"name":"Chicago Cosmetic Surgery and Dermatology, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Schlessinger","sequence":"additional","affiliation":[{"name":"Advanced Skin Research Center, Omaha, Nebraska;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Joseph","sequence":"additional","affiliation":[{"name":"Clinical Testing of Beverly Hills, Encino, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joely","family":"Kaufman-Janette","sequence":"additional","affiliation":[{"name":"Skin Associates of South Florida, Skin Research Institute, Coral Gables, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"El-Qadi","sequence":"additional","affiliation":[{"name":"Galderma, Dallas, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Persson","sequence":"additional","affiliation":[{"name":"Galderma, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Prygova","sequence":"additional","affiliation":[{"name":"Galderma, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"R3-20241006","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1007\/s00266-018-1200-4","article-title":"Assessment of subject and physician satisfaction after long-term treatment of glabellar lines with AbobotulinumtoxinA (Dysport\u00ae\/Azzalure\u00ae): primary results of the APPEAL noninterventional study","volume":"42","author":"Gubanova","year":"2018","journal-title":"Aesthetic Plast Surg"},{"key":"R4-20241006","first-page":"E56","article-title":"Onset and duration of AbobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review","volume":"13","author":"Nestor","year":"2020","journal-title":"J Clin Aesthet Dermatol"},{"key":"R5-20241006","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1111\/j.1524-4725.2006.32327.x","article-title":"Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients","volume":"33","author":"Rzany","year":"2007","journal-title":"Dermatol Surg"},{"key":"R6-20241006","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/DSS.0000000000002846","article-title":"A multicenter study to evaluate subject satisfaction with two treatments of AbobotulinumtoxinA a year in the glabellar lines","volume":"47","author":"Schlessinger","year":"2021","journal-title":"Dermatol Surg"},{"key":"R7-20241006","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/j.1524-4725.2009.01235.x","article-title":"Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety","volume":"35","author":"Brandt","year":"2009","journal-title":"Dermatol Surg"},{"key":"R8-20241006","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/DSS.0000000000002013","article-title":"Efficacy, safety, and subject satisfaction after AbobotulinumtoxinA treatment for moderate to severe glabellar lines","volume":"46","author":"Monheit","year":"2020","journal-title":"Dermatol Surg"},{"key":"R9-20241006","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archfaci.2009.5","article-title":"Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines","volume":"11","author":"Moy","year":"2009","journal-title":"Arch Facial Plast Surg"},{"key":"R10-20241006","first-page":"439","article-title":"The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment","volume":"8","author":"Rubin","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"R13-20241006","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dsu.12404","article-title":"Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study","volume":"40","author":"Schlessinger","year":"2014","journal-title":"Dermatol Surg"},{"key":"R12-20241006","doi-asserted-by":"crossref","first-page":"980","DOI":"10.36849\/JDD.6263","article-title":"AbobotulinumtoxinA for the treatment of moderate-to-severe glabellar lines: a randomized, dose-escalating, double-blind study","volume":"20","author":"Joseph","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"R17-20241006","first-page":"1544","article-title":"Does increasing the dose of abobotulinumtoxina impact the duration of effectiveness for the treatment of moderate to severe glabellar lines?","volume":"15","author":"Joseph","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"R14-20241006","doi-asserted-by":"crossref","first-page":"988","DOI":"10.36849\/JDD.6130","article-title":"AbobotulinumtoxinA treatment of glabellar lines using a new reconstitution and injection volume: randomized, placebo-controlled data","volume":"20","author":"Schlessinger","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"R15-20241006","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jocd.14906","article-title":"Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines","volume":"21","author":"Dayan","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"R16-20241006","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1111\/j.1524-4725.2006.32332.x","article-title":"A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose","volume":"33","author":"Monheit","year":"2007","journal-title":"Dermatol Surg"},{"key":"R18-20241006","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/PSN.0000000000000292","article-title":"AbobotulinumtoxinA for facial rejuvenation: what affects the duration of efficacy?","volume":"40","author":"Warren","year":"2020","journal-title":"Plast Surg Nurs"},{"key":"R11-20241006","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/asj\/sjw282","article-title":"Key parameters for the use of AbobotulinumtoxinA in aesthetics: onset and duration","volume":"37","author":"Nestor","year":"2017","journal-title":"Aesthet Surg J"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T03:15:22Z","timestamp":1728184522000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":16,"journal-issue":{"issue":"9S","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004347","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}